Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Rybniker

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Microbiology Insights|August 7, 2019
The Expanding Role of p38 Mitogen-Activated Protein Kinase in Programmed Host Cell DeathJessica Gräb, Jan Rybniker
The Lancet. Infectious Diseases|May 19, 2020
Importance of precise data on SARS-CoV-2 transmission dynamics controlJan Rybniker, Gerd Fätkenheuer
Molecular Systems Biology|September 12, 2022
Monocyte-crosstalk drives interferon-mediated signaling following SARS-CoV-2 exposureSebastian J Theobald, Jan Rybniker
Cell Host & Microbe|June 26, 2026
Predicting antimicrobial resistance for precision medicineTheresa Fink, Jan Rybniker, Tobias Bollenbach
Current Opinion in Biotechnology|April 21, 2017
Novel and revisited approaches in antituberculosis drug discoveryJennifer Herrmann, Jan Rybniker, Rolf Müller
Journal of Medical Microbiology|January 3, 2006
Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis--application for identification and susceptibility testingJan Rybniker, Stefanie Kramme, Pamela L Small
Journal of Bacteriology|February 20, 2003
Transposition of Tn5367 in Mycobacterium marinum, using a conditionally recombinant mycobacteriophageJan Rybniker, Martina Wolke, Christiane Haefs, et al.
Deutsche Medizinische Wochenschrift (1946)|September 29, 2025
[Extrapulmonary tuberculosis]Angela Klingmüller, Jonathan Steinke, Jan Rybniker, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2018
No Evidence for Acquired Mutations Associated with Cytochrome <i>bc</i><sub>1</sub> Inhibitor Resistance in 13,559 Clinical Mycobacterium tuberculosis Complex IsolatesJan Rybniker, Thomas Andreas Kohl, Ivan Barilar, et al.
EMBO Molecular Medicine|January 10, 2014
Tuberculosis drug discovery in the post-post-genomic eraBenoit Lechartier, Jan Rybniker, Alimuddin Zumla, et al.
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Microbiology Insights|August 7, 2019
The Expanding Role of p38 Mitogen-Activated Protein Kinase in Programmed Host Cell DeathJessica Gräb, Jan Rybniker
The Lancet. Infectious Diseases|May 19, 2020
Importance of precise data on SARS-CoV-2 transmission dynamics controlJan Rybniker, Gerd Fätkenheuer
Molecular Systems Biology|September 12, 2022
Monocyte-crosstalk drives interferon-mediated signaling following SARS-CoV-2 exposureSebastian J Theobald, Jan Rybniker
Cell Host & Microbe|June 26, 2026
Predicting antimicrobial resistance for precision medicineTheresa Fink, Jan Rybniker, Tobias Bollenbach
Current Opinion in Biotechnology|April 21, 2017
Novel and revisited approaches in antituberculosis drug discoveryJennifer Herrmann, Jan Rybniker, Rolf Müller
Journal of Medical Microbiology|January 3, 2006
Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis--application for identification and susceptibility testingJan Rybniker, Stefanie Kramme, Pamela L Small
Journal of Bacteriology|February 20, 2003
Transposition of Tn5367 in Mycobacterium marinum, using a conditionally recombinant mycobacteriophageJan Rybniker, Martina Wolke, Christiane Haefs, et al.
Deutsche Medizinische Wochenschrift (1946)|September 29, 2025
[Extrapulmonary tuberculosis]Angela Klingmüller, Jonathan Steinke, Jan Rybniker, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2018
No Evidence for Acquired Mutations Associated with Cytochrome <i>bc</i><sub>1</sub> Inhibitor Resistance in 13,559 Clinical Mycobacterium tuberculosis Complex IsolatesJan Rybniker, Thomas Andreas Kohl, Ivan Barilar, et al.
EMBO Molecular Medicine|January 10, 2014
Tuberculosis drug discovery in the post-post-genomic eraBenoit Lechartier, Jan Rybniker, Alimuddin Zumla, et al.
Pageof 12